Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy

Liu, Limin; Liu, Shangyu; Shen, Lishui; Tu, Bin; Hu, Zhicheng; Hu, Feng; Zheng, Lihui; Ding, Ligang; Fan, Xiaohan; Yao, Yan

doi:10.1002/clc.23425

Cited by 6 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that patients with elevated levels of cTnI and CK-MB had more severe clinical phenotypes, consistent with previous reports. [8][9][10][11][12] The elevated levels of cTnI and CK-MB were associated with greater LV wall thickness, presumably because thicker myocardium causes more severe intimal hyperplasia and luminal reduction within coronary arteries, triggering microvascular dysfunction. 22,23 Consequently, the coronary arterial supply is insufficient.…”

Section: Discussionmentioning

confidence: 99%

“…The results of small-scale studies have suggested associations between troponins/CK-MB and the extents of hypertrophy, 8 myocardial strain, 9,10 cardiac fibrosis, 11 arrhythmia, 12 and mortality 13 among patients with HCM. However, the existing evidence is insufficient to warrant the inclusion of troponins and CK-MB in the risk stratification strategies for HCM.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy

Zhang,

Liu,

Zhang

et al. 2024

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

Background: Serum troponins and CK-MB (creatine kinase-MB) are readily detectable and reliable cardiac-specific biomarkers of subclinical myocardial injury. This study explores the roles of cTnI (cardiac troponin I) and CK-MB in hypertrophic cardiomyopathy (HCM). Methods: This study included 1045 patients with HCM who had baseline cTnI and CK-MB measurements at Fuwai Hospital between 1999 and 2019. Patients were excluded if they had undergone percutaneous coronary intervention or coronary artery bypass grafting, or had renal failure. Five end points were studied: all-cause death, cardiovascular death, noncardiovascular death, sudden cardiac death, and other cardiovascular death. Cox regression was used to assess the associations of cTnI and CK-MB levels with outcomes. Results: Nine hundred seventy patients with available follow-up data were finally analyzed (mean age, 49.3 years; 36.4% female). During the median 4.3-year follow-up period, 87 patients reached the end points. Higher cTnI (per 0.05 ng/mL increase) and CK-MB (per 1 IU/L increase) levels were associated with increased risks of all-cause death (cTnI: adjusted hazard ratio [HR], 1.038, P <0.001; CK-MB: adjusted HR, 1.021, P =0.004), cardiovascular death (cTnI: adjusted HR, 1.040, P <0.001; CK-MB: adjusted HR, 1.025, P =0.006), and sudden cardiac death (cTnI: adjusted HR, 1.045, P <0.001; CK-MB: adjusted HR, 1.032, P =0.001). Patients with elevated levels of both cTnI and CK-MB had worse prognoses than patients with an elevated level of either biomarker alone and patients who did not have an elevated level of either biomarker. Addition of the binary indicator elevation of both cTnI and CK-MB significantly improved the discrimination and reclassification abilities of the standard HCM Risk- sudden cardiac death model (C statistics: P =0.002; net reclassification improvement, 0.652; integrated discrimination improvement, 0.064). Conclusions: Comprehensive evaluations of biomarkers of myocardial injury, cTnI and CK-MB, have considerable value for predicting adverse outcomes among patients with HCM. Routine cTnI and CK-MB assessments may help to guide implantable cardioverter defibrillator implantation for primary prevention in HCM.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy

Zhang,

Liu,

Zhang

et al. 2024

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

show abstract

“…Furthermore, several studies have investigated the prognostic role of cTNI with regard to the occurrence of ventricular tachyarrhythmias. For instance, Liu et al found that elevated cTNI levels were associated with the occurrence of nonsustained VT in 755 patients with hypertrophic obstructive cardiomyopathy [ 36 ]. However, cTNI did not affect the risk of the composite arrhythmic endpoint (i.e., recurrent ventricular tachyarrhythmias, appropriate ICD therapies and SCD) at long-term follow-up.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias

Akın

Behnes

Müller

et al. 2022

JCM

View full text Add to dashboard Cite

Besides the diagnostic role in acute myocardial infarction, cardiac troponin I levels (cTNI) may be increased in various other clinical conditions, including heart failure, valvular heart disease and sepsis. However, limited data are available regarding the prognostic role of cTNI in the setting of ventricular tachyarrhythmias. Therefore, the present study sought to assess the prognostic impact of cTNI in patients with ventricular tachyarrhythmias (i.e., ventricular tachycardia (VT) and fibrillation (VF)) on admission. A large retrospective registry was used, including all consecutive patients presenting with ventricular tachyarrhythmias from 2002 to 2015. The prognostic impact of elevated cTNI levels was investigated for 30-day all-cause mortality (i.e., primary endpoint) using Kaplan–Meier, receiver operating characteristic (ROC), multivariable Cox regression analyses and propensity score matching. From a total of 1104 patients with ventricular tachyarrhythmias and available cTNI levels on admission, 46% were admitted with VT and 54% with VF. At 30 days, high cTNI was associated with the primary endpoint (40% vs. 22%; log rank p = 0.001; HR = 2.004; 95% CI 1.603–2.505; p = 0.001), which was still evident after multivariable adjustment and propensity score matching (30% vs. 18%; log rank p = 0.003; HR = 1.729; 95% CI 1.184–2.525; p = 0.005). Significant discrimination of the primary endpoint was especially evident in VT patients (area under the curve (AUC) 0.734; 95% CI 0.645–0.823; p = 0.001). In contrast, secondary endpoints, including all-cause mortality at 30 months and a composite arrhythmic endpoint, were not affected by cTNI levels. The risk of cardiac rehospitalization was lower in patients with high cTNI, which was no longer observed after propensity score matching. In conclusion, high cTNI levels were associated with increased risk of all-cause mortality at 30 days in patients presenting with ventricular tachyarrhythmias.

show abstract

“…CTnI is an important index to evaluate the therapeutic effect and prognosis of patients with heart disease. 15 Therefore, in patients with acute heart failure complicated with respiratory failure, monitoring of NT-pro BNP and cTnI levels in addition to blood gas analysis indexes may help in inhibiting the progress and aggravation of heart failure. Our study showed that the expression of NT-pro BNP and cTnI in the NIV group was lower than that in the control group, which was consistent with the results of Westhoff M and De Palo M. 16,17 Noninvasive ventilator-assisted ventilation technology is easy and safe.…”

Section: Discussionmentioning

confidence: 99%

Changes of blood gas and serum indexes in patients with acute heart failure complicated with respiratory failure treated by noninvasive ventilator

Yuan¹,

Hong²,

Yang³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To observe the changes of blood gas and serum indexes in patients with acute heart failure complicated with respiratory failure treated by noninvasive ventilator-assisted ventilation. Methods: The records of patients with acute heart failure and respiratory failure, treated in our hospital from June 2019 to June 2021, were selected and stratified based on the received therapy. Of a total of 168 patients, 81 received continuous low flow oxygen therapy (control group) and 87 received noninvasive ventilator (NIV)-assisted ventilation therapy (NIV group). The blood gas and serum indexes of the two groups were compared and analyzed. Results: After 48 hours of treatment, the blood oxygen saturation (SaO2), arterial partial pressure of oxygen (PaO2) and oxygenation index (PaO2/FiO2) in patients in the NIV group were higher than those in the control group, while the expression of arterial partial pressure of carbon dioxide (PaCO2) was lower than that in the control group (P<0.05). After 24 hours and 48 hours of treatment, there was an increase in the expression of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) and Cardiac troponin I (cTnI) in both groups. The expression of NT-pro BNP and cTnI in the NIV group was significantly lower than that in the control group (P<0.05). Conclusion: In patients with acute heart failure and respiratory failure, noninvasive ventilator-assisted ventilation results in improved blood gas analysis indexes and lower levels of heart disease markers, NT-pro BNP and cTnI. doi: https://doi.org/10.12669/pjms.38.7.6526 How to cite this:Wu Y, Hong X, Yang N, Zhang R, Shi Y. Changes of blood gas and serum indexes in patients with acute heart failure complicated with respiratory failure treated by noninvasive ventilator. Pak J Med Sci. 2022;38(7):1766-1770. doi: https://doi.org/10.12669/pjms.38.7.6526 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Correlations between cardiac troponin I and nonsustained ventricular tachycardia in hypertrophic obstructive cardiomyopathy

Cited by 6 publications

References 45 publications

Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy

Role of Biomarkers of Myocardial Injury to Predict Adverse Outcomes in Hypertrophic Cardiomyopathy

Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias

Changes of blood gas and serum indexes in patients with acute heart failure complicated with respiratory failure treated by noninvasive ventilator

Contact Info

Product

Resources

About